Publication: 2413

Publication: 2413

Blood‐based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Cancer Med vol 5 (9) 2249-2260

Year:: 2016
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: collection

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 6

Parents:: 2138
Children:: None

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: Bristol Myers; Sanofi-Synthelabo
Grants:: U24CA196171, U10 CA180821, U10 CA180882, , U10 CA047577, U10 CA031946, U10 CA033601, U24 CA196171, U10 CA180867, U10 CA180838

Corr. Author:
Authors:: Ace J. Hatch Alexander B. Sibley Mark D. Starr J. Chris Brady Chen Jiang Jingquan Jia Daniel L. Bowers Herbert Pang Kouros Owzar Donna Niedzwiecki Federico Innocenti Alan P. Venook Herbert I. Hurwitz Andrew B. Nixon

Networks:: CA824, LAPS-MA036, LAPS-NC007, LAPS-NC010, MD001

Study: CALGB-80203
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Biomarker, cetuximab, colorectal cancer, plasma